Physician
Watauga Medical Center INC
Watauga Medical Center INC was paid $1.44M by Medicaid between Jan 2018 and Dec 2024, across 92 billing codes. Its largest line is 99283, emergency room visit (moderate) — 31% of everything it billed.
33Billing provider infoWATAUGA MEDICAL CENTER INC
BOONE, NC 28607
BOONE, NC 28607
33aNPI1205859766assigned 07/25/2006
33bProvider typeCardiovascular Disease Physician
28Total paid$1.44M
24GClaims68,472
24DCodes billed92
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Cardiovascular Disease Physician providers in North Carolina
Rank by total paid#6 of 109
Median peer was paid$58K
This provider vs. median25×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LONG, MARY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,789 | $130K | |
| 2019 | 9,440 | $117K | |
| 2020 | 7,123 | $56K | |
| 2021 | 9,338 | $118K | |
| 2022 | 10,186 | $189K | |
| 2023 | 9,394 | $258K | |
| 2024incomplete | 13,202 | $574K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 5,744 | 5,224 | $447K |
| 41899 | Unlisted procedure, dentoalveolar structures | 13% | 119 | 108 | $192K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.6% | 786 | 704 | $109K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.7% | 6,840 | 5,212 | $82K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.0% | 13,177 | 9,379 | $72K |
| J3490 | Unclassified drugs | 4.6% | 2,807 | 1,386 | $67K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 4.2% | 401 | 344 | $61K |
| 80053 | Comprehensive metabolic panel | 4.0% | 9,994 | 6,887 | $58K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 950 | 864 | $49K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 2.4% | 38 | 38 | $34K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 31 | 27 | $26K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 837 | 748 | $21K |
80 more codes
| 99285 | Emergency room visit (most serious) | 1.2% | 103 | $17K |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 10,136 | $15K |
| 83735 | <1% | 2,986 | $14K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 96 | $12K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 190 | $12K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 248 | $11K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 434 | $9K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 74 | $9K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 341 | $9K |
| 82728 | <1% | 925 | $8K | |
| 36591 | <1% | 515 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 65 | $5K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 49 | $5K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 104 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 517 | $5K |
| 83550 | <1% | 900 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 247 | $5K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 17 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 432 | $5K |
| 71045 | Radiologic examination, chest; single view | <1% | 147 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 261 | $4K |
| 83540 | <1% | 900 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 125 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 125 | $3K |
| 88342 | <1% | 55 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 301 | $2K |
| 81001 | <1% | 691 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 64 | $2K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 12 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 82 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 406 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 29 | $2K |
| 86140 | <1% | 291 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 175 | $2K |
| 84484 | <1% | 167 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12 | $1K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 67 | $1K |
| 83690 | <1% | 170 | $1K | |
| 87634 | <1% | 13 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 29 | $1K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 13 | $1K |
| 80076 | <1% | 222 | $989.01 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 150 | $964.99 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 15 | $938.94 |
| 85652 | <1% | 295 | $906.09 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 171 | $788.37 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 29 | $725.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 118 | $712.13 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 14 | $667.54 |
| 87486 | <1% | 17 | $592.91 | |
| 87581 | <1% | 17 | $592.91 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 17 | $592.91 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 24 | $491.87 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 31 | $482.70 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 54 | $429.37 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 43 | $429.04 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 366 | $424.11 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 12 | $390.01 |
| 86850 | <1% | 38 | $346.30 | |
| 83605 | <1% | 26 | $294.58 | |
| 88142 | <1% | 16 | $277.64 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14 | $274.54 |
| 87641 | <1% | 23 | $255.56 | |
| 84703 | <1% | 26 | $239.49 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,928 | $223.81 |
| 82947 | <1% | 49 | $172.17 | |
| 85379 | <1% | 13 | $131.89 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 98 | $123.41 |
| 85610 | <1% | 48 | $118.27 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 12 | $111.24 |
| 85730 | <1% | 26 | $73.62 | |
| 86592 | <1% | 13 | $63.72 | |
| 86901 | <1% | 38 | $60.25 | |
| 86900 | <1% | 38 | $60.25 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 17 | $57.87 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 14 | $45.04 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 17 | $39.92 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 144 | $20.46 |
| A9270 | Non-covered item or service | 0% | 29 | $0.00 |
| 99203 | Doctor's office visit, new patient (routine) | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLONG, MARY (SR VP MEDICAL STAFF RELATIONS)
Parent organizationAPPALACHIAN REGIONAL HEALTHCARE SYSTEM
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.